TY - JOUR
T1 - Tissue damage of different submucosal injection solutions for EMR
AU - Fujishiro, Mitsuhiro
AU - Yahagi, Naohisa
AU - Kashimura, Koji
AU - Matsuura, Toyokazu
AU - Nakamura, Masanori
AU - Kakushima, Naomi
AU - Kodashima, Shinya
AU - Ono, Satoshi
AU - Kobayashi, Katsuya
AU - Hashimoto, Takuhei
AU - Yamamichi, Nobutake
AU - Tateishi, Ayako
AU - Shimizu, Yasuhito
AU - Oka, Masashi
AU - Ichinose, Masao
AU - Omata, Masao
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/12
Y1 - 2005/12
N2 - Background: When choosing submucosal injection solutions for EMR, tissue damage should be considered, as well as the lesion-lifting ability. The objective of the study was to find out the potential tissue damage of submucosal injection solutions. Methods: The submucosal injection solutions examined were the following: normal saline solution (NS), 3.75% NaCl, 20% and 50% dextrose water (DW), a glycerin solution (Glyceol; 10% glycerin with 0.9% NaCl plus 5% fructose), and two hyaluronic acid (HA) solutions (0.25% 1900 kDa/NS solution and 0.125% 1900 kDa/ Glyceol solution). Furthermore, DW with different concentrations (5%, 10%, 15%, 30%, 40%) also was examined to find out the tolerable concentration without tissue damage. A total of 2 mL of each solution per stomach were injected by endoscopy into the submucosal layer at the separate sites of 4 living minipigs. Two minipigs were euthanized after 30 minutes of endoscopic observations, and the others were euthanized after additional endoscopic observations a week after injection. Results: There was no apparent tissue damage in NS, 5% and 10% DW, Glyceol, or two solutions of HA, whereas, hypertonic solutions, except Glyceol and 10% DW, have more or less potency of tissue damage. In 3.75% NaCl and DW with concentrations of ≥20%, considerable tissue damage was observed, which might affect resected EMR specimens and ulcer healing. Conclusions: Use of hypertonic solutions except Glyceol is not recommended with respect to tissue damage. A combination of HA and Glyceol is the most favorable submucosal injection solution, considering tissue damage and lesion-lifting ability.
AB - Background: When choosing submucosal injection solutions for EMR, tissue damage should be considered, as well as the lesion-lifting ability. The objective of the study was to find out the potential tissue damage of submucosal injection solutions. Methods: The submucosal injection solutions examined were the following: normal saline solution (NS), 3.75% NaCl, 20% and 50% dextrose water (DW), a glycerin solution (Glyceol; 10% glycerin with 0.9% NaCl plus 5% fructose), and two hyaluronic acid (HA) solutions (0.25% 1900 kDa/NS solution and 0.125% 1900 kDa/ Glyceol solution). Furthermore, DW with different concentrations (5%, 10%, 15%, 30%, 40%) also was examined to find out the tolerable concentration without tissue damage. A total of 2 mL of each solution per stomach were injected by endoscopy into the submucosal layer at the separate sites of 4 living minipigs. Two minipigs were euthanized after 30 minutes of endoscopic observations, and the others were euthanized after additional endoscopic observations a week after injection. Results: There was no apparent tissue damage in NS, 5% and 10% DW, Glyceol, or two solutions of HA, whereas, hypertonic solutions, except Glyceol and 10% DW, have more or less potency of tissue damage. In 3.75% NaCl and DW with concentrations of ≥20%, considerable tissue damage was observed, which might affect resected EMR specimens and ulcer healing. Conclusions: Use of hypertonic solutions except Glyceol is not recommended with respect to tissue damage. A combination of HA and Glyceol is the most favorable submucosal injection solution, considering tissue damage and lesion-lifting ability.
UR - http://www.scopus.com/inward/record.url?scp=27844475653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27844475653&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2005.07.052
DO - 10.1016/j.gie.2005.07.052
M3 - Article
C2 - 16301040
AN - SCOPUS:27844475653
SN - 0016-5107
VL - 62
SP - 933
EP - 942
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 6
ER -